Show Notes
Anticholinergic drug use is on the rise due to the COVID-19 pandemic and the UK medicines regulator is also considering extending access to the anticholinergic bladder drug oxybutynin over the counter.
In this episode, we will look at the potential implications of these changes, particularly in older people, and examine the case for deprescribing. We will also assess emerging evidence that suggests that the cumulative burden of anticholinergics over a lifetime could be a causal factor for dementia.
Thank you to Graham Stretch, chief pharmacist at the Argyle Group in west London, his patient Miriam* who agreed for us to record her consultation, and also to Chris Fox, professor of clinical psychiatry at the University of East Anglia.
This programme is presented by executive editor Nigel Praities and senior data journalist Julia Robinson. It was produced by Geoff Marsh.
*Some details have been changed to ensure confidentiality.
More from The PJ Pod
For Tase Oputu, becoming the first president of the Royal College of Pharmacy is “the greatest honour of my career”, and she says the move to a royal college is already changing how pharmacy is received by policymakers.
In this episode of Pharmacy Inside Jobs, senior editor, research and learning Alex Clabburn talks to Ed Hindle.
Electronic Prescription System (EPS) nominations connect patients with the pharmacy where they can collect their medication – and often access other services, help and advice while they’re there.
In this episode of Pharmacy Inside Jobs, Joanna Robertson, senior clinical reporter, talks to Mark Stuart, a sports pharmacist whose 25-year career has spanned Olympic, Paralympic and Commonwealth games, as well as anti-doping education at the International Testing Agency.
In this episode of The PJ Pod, senior features editor Siobhan Chan examines how the issue of antimicrobial resistance (AMR) is being communicated outside of traditional clinical and policy settings.